Mar 7, 2024 | Press Releases
CUPERTINO, Calif., March 07, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Feb 20, 2024 | Press Releases
CUPERTINO, Calif., Feb. 20, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Feb 6, 2024 | Press Releases
Virtual event on Thursday, February 15, 2024 at 12:00 PM ET will feature KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCGCUPERTINO, Calif., Feb. 06, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)...
Jan 25, 2024 | Press Releases
CUPERTINO, Calif., Jan. 25, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Jan 10, 2024 | Press Releases
CUPERTINO, CA / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Jan 4, 2024 | Press Releases
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supporting a differentiated profile for once-daily brilaroxazine...
